Neal Shore, MD, FACS, highlights his recent research on the effects of apalutamide plus androgen deprivation therapy on the biochemical recurrence-free rate in patients with high-risk localized prostate cancer who underwent radical prostatectomy.
Apalutamide, ADT Improve Outcomes in High-Risk Prostate Cancer Post-Surgery
By Neal Shore, MD, FACS - Last Updated: June 13, 2024Related Posts
Dr. Sonpavde showcases a phase I/Ib clincial trial on the safety of a neoadjuvant darolutamide and relugolix combination.
Dr. Keizman showcases his research on using Decipher for early prostate cancer for USA versus non-USA populations.
Dr. Ghoreifi characterizes the activity of inflammasome genes and their association with oncological outcomes in PC.
Patients with very high-risk disease saw greater benefit from long-term ADT use compared to those with high-risk disease.
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.